Overexpression of BCR-ABL and P-glycoprotein (Pgp) are two of the known mechanisms of imatinib resistance. As combination therapy may allow to overcome drug resistance, we investigated the effect of combination treatment with imatinib and 17-allylamino-17-demethoxygeldanamycin (17-AAG), a heat-shock protein 90 (Hsp90) inhibitor, on different imatinib-sensitive and imatinib-resistant CML cell lines. In imatinib-sensitive cells, combination index (CI) values obtained using the method of Chou and Talalay indicated additive (CI ¼ 1) or marginally antagonistic (CI41) effects following simultaneous treatment with imatinib and 17-AAG. In imatinib-resistant cells both drugs acted synergistically (CIo1). In primary chronic-phase CML cells additive or synergistic effects of the combination of imatinib plus 17-AAG were discernible. Annexin V/propidium iodide staining showed that the activity of imatinib plus 17-AAG is mediated by apoptosis. Combination treatment with imatinib plus 17-AAG was more effective in reducing the BCR-ABL protein level than 17-AAG alone. Monotherapy with 17-AAG decreased P-glycoprotein activity, which may increase intracellular imatinib levels and contribute to the sensitization of CML cells to imatinib. The results suggest that combination of imatinib and 17-AAG may be useful to overcome imatinib resistance in a clinical setting.
Introduction
Chronic myelogenous leukemia (CML) has gained outstanding importance for targeted cancer therapy. Inhibition of the BCR-ABL tyrosine kinase by imatinib (STI571, Glivec s , Gleevect) leads to reduced proliferation of CML cells in vitro, and sustained hematological, cytogenetic and molecular responses in chronic phase, accelerated phase and blast crisis of CML could be achieved in clinical studies. [1] [2] [3] However, resistance has been observed after various periods of imatinib monotherapy, especially in advanced stages of disease. Reported mechanisms of resistance to imatinib are overexpression of BCR-ABL transcripts, genomic amplification of the BCR-ABL fusion gene, point mutations of the tyrosine kinase domain and occurrence of additional chromosomal aberrations resulting in clonal evolution. [4] [5] [6] [7] Overexpression of P-glycoprotein (Pgp), encoded by the multidrug resistance 1 (MDR1) gene, as a possible mechanism of resistance to imatinib has been observed in vitro. 8, 9 Combination of imatinib with other agents may allow to overcome resistance to monotherapy. [10] [11] [12] In our study we used 17-allylamino-17-demethoxygeldanamycin (17-AAG) that inhibits the function of the heat-shock protein 90 (Hsp90) and thus destabilizes the complex of Hsp90 and BCR-ABL followed by degradation of the BCR-ABL tyrosine kinase by the proteasome. We investigated whether synergistic activity of both drugs in imatinib-sensitive or -resistant BCR-ABL-positive cells could be observed. Since a recent report by Illmer et al 13 uncovered imatinib to be a substrate for Pgp, we investigated additionally the effect of 17-AAG on Pgp function.
Materials and methods

Cell lines
BCR-ABL-positive BV173, EM3, K562 and LAMA84 CML cell lines were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). Imatinibresistant LAMA84 (LAMA84-R) and K562 (K562-R) cells were cultured in the lab of Dr J Melo (London). 8 Cells were maintained under standard culture conditions (37 1C, fully humidified atmosphere, 5% CO 2 ) in RPMI-1640 medium supplemented with 10% inactivated fetal calf serum (FCS) and penicillin/ streptomycin (Invitrogen, Karlsruhe, Germany). LAMA84-R and K562-R were cultured in medium containing 1 mM imatinib.
Patient samples
Primary CML cells were isolated by Ficoll density gradient centrifugation (Biocoll separation solution, density 1.077 g/ml, Biochrom, Berlin, Germany) from peripheral blood of three patients with newly diagnosed CML (imatinib-sensitive, blast crisis) and three patients refractory to imatinib therapy (imatinibresistant, blast crisis (two patients) and chronic phase (one patient)). The study was approved by the local ethical committee and informed consent was obtained from all patients. After separation mononuclear cells were frozen in Iscove's modified Dulbecco's medium with 50% FCS and 10% DMSO and stored at À801C until investigation.
Drugs
Imatinib was kindly provided by Novartis Pharma (Basel, Switzerland), 17-AAG by the developmental therapeutics branch of Cancer Therapy Evaluation Program, National Cancer Institute, NIH (Bethesda, MD, USA). SU5614 was obtained from Merck (Darmstadt, Germany). Imatinib was dissolved in sterile Dulbecco's phosphate-buffered saline (Dulbecco's PBS; Invitrogen), 17-AAG and SU5614 in dimethyl sulfoxide. Aliquots of all drugs concentrated at 10 mM were stored at À20 1C until use. For experiments, serial dilutions were prepared.
MTT assay
The MTT assay was used for the assessment of cell growth inhibition as described previously.
14 Cells were treated for 48 h with six increasing concentrations (doubling with each increment) of the drugs alone or the combination of both. For the combination, the ratio of both drugs was based on equitoxic drug concentrations (for details, see Topaly et al 10 ). Using the CalcuSyn Software (Biosoft, Cambridge, UK) analysis of doseeffect relationships was performed according to the medianeffect method of Chou and Talalay and mean combination index (CI) values and standard deviations were calculated for three independent experiments. CIo1, CI ¼ 1 or CI41 represent synergism, additivity or antagonism of both drugs, respectively. 15 As CI values depend on the levels of growth inhibition (Fraction affected, Fa) they are observed at, data are presented in CI vs Fa plots.
Colony-forming cell (CFC) assay
Cells were plated in duplicate in MethoCult GF H4534 methylcellulose (Stem Cell Technologies, Vancouver, BC, Canada) and incubated for 14 days without drugs, with three different concentrations of either imatinib or 17-AAG alone or with the combination of both. Individual colony-forming units granulocyte/macrophage (CFU-GM) were counted, expressed as percent of untreated control and Fa and CI values were calculated. Titration of cell number was performed in order to achieve about 100 CFU-GM after 14 days of incubation in untreated samples.
Apoptosis assay
The annexin V/propidium iodide apoptosis assay was performed using an Annexin V-FITC Kit (Immunotech, Marseille, France) 48 h after start of incubation of cells according to the manufacturer's protocol. The data were collected and analyzed with a FACScalibur flow cytometer (Becton Dickinson, Heidelberg, Germany) using the CellQuest Software (Becton Dickinson).
Western blot analysis
A total of 5 Â 10 6 cells were incubated with imatinib, 17-AAG or a combination of both for 48 h (for concentrations see Figure 4 ). SU5614, a specific inhibitor of the PDGF receptor (PDGFR) kinase, was applied at concentrations of 1, 5 or 10 mM; incubation time was 24, 48 or 72 h. After incubation cells were harvested, washed with ice-cold PBS, resuspended in 150 ml lysis buffer (containing 10 mM Tris HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.5% Na-Desoxycholate, 1 mM DTT, and Complete Protease Inhibitor Cocktail solution according to the manufacturer's instructions (Roche, Mannheim, Germany)) and centrifuged at 13 000 g for 10 min at 41C; the supernatant was used as cell extract.
For Western blot analysis, SDS-polyacrylamide gel electrophoresis (SDS-PAGE 8-12.5%) was performed according to Laemmli. 16 Protein concentrations were determined by the Bradford method (BIO-RAD Laboratories, Munich, Germany). Proteins were transferred to a nitrocellulose membrane (Hybond-C Extra, 0.45 mm, Amersham and Immobilon, Millipore, Bedford, MA, USA) by standard electroblotting, probed with individual antibodies, and visualized using the ECL system (Amersham Bioscience Europe, Germany). The following antibodies were used: anti-BCR (sc-885), anti-Hsp90 (sc-7947), antiHsp70 (sc-1060), anti-CRKL (sc-319, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Secondary antibodies were horseradish peroxidase-conjugated antimouse, antirabbit and antigoat IgGs (Santa Cruz Biotechnology and DAKO, Glostrup, Denmark). To control for equal protein loading, the blots were stripped and reprobed with an anti-b-actin antibody (Sigma, Munich, Germany).
Quantitative real-time PCR
RNA isolation and subsequent reverse transcription with TaqMan s Reverse Transcription Reagents (Applied Biosystems, Weiterstadt, Germany) was performed as described previously. 17 The primers for BCR-ABL were a2-fp 5 0 -AGCGGCTT CACTCAGACCCT-3 0 and b23-rp 5 0 -CTGACCATCAATAAGGA AGAAGCC-3 0 . For detection, the TaqMan s probe a2-p 5 0 -CTCAAAGTCAGATGCTACTGGCCGCTGA-3 0 was applied.
Fluorescence in situ hybridization (FISH)
Metaphase spreads of imatinib-sensitive and imatinib-resistant LAMA84 and K562 cells were prepared by standard protocols. Two-color FISH using a commercial probe set for the BCR-ABL translocation (QBiogene, Illkirch, France) was performed according to the manufacturer's instructions. Images of 10 metaphase spreads were acquired using a Leica DM RXA epifluorescence microscope (Leica, Bensheim, Germany) equipped with a Sensys CCD camera (Photometrics, Tucson, AZ, USA) and controlled by the Leica Q-FISH software (Leica Microsystems Imaging Solution, Cambridge, UK). Slides were destained and a ReFISH protocol described by Mü ller et al 18 was applied to allow multifluor in situ hybridization (M-FISH) of combinatorially labeled chromosome painting probes. 19 Images of the same 10 metaphase spreads were evaluated and processed using the Leica MCK software.
Sequence of the ABL kinase domain
The kinase domain of ABL was amplified, sequenced and analyzed according to a previously described method. 8 
Rhodamine-123 efflux assay
In total, 2 Â 10 5 cells were incubated with different concentrations of 17-AAG including a negative control with PBS treatment. After 1 h cells were harvested and to each sample, 0.2 mg/ml rhodamine-123 ( 123 Rh) (Fluka, Buchs, Switzerland) was added (a cell sample containing 123 Rh and 2 mM of the specific and potent Pgp inhibitor cyclosporin A (CsA) was included as positive control) and incubated at 37 1C for 30 min Synergism of imatinib and 17-AAG( 123 Rh uptake step). Then cells were washed twice with PBS/4% FCS, resuspended in RPMI-1640 and incubated at 371C ( 123 Rh efflux step). After 1 h, cells were washed again, resuspended in ice-cold PBS and kept on ice until measurement. In every step, all buffers and media contained adequate concentrations of 17-AAG or CsA, respectively. In order to determine and exclude the fraction of dead cells, 1 mg/ml propidium iodide was added and the samples were analyzed for the level of rhodamine fluorescence using a FACScalibur flow cytometer (Becton Dickinson). The mean fluorescence intensity (MFI) of 10 000 cells was used for comparison among different cell lines and experimental conditions.
Statistics
Three independent experiments were performed, if not indicated otherwise, and mean values and standard deviations were calculated. Statistical significance of synergistic action in the apoptosis assay was assessed by the test for interaction effects with analysis of variance (ANOVA) using the software package R, version 1.9.1 (R-Development-Core-Team, 2003).
Results
Inhibition of proliferation
For single agent treatment, the IC 50 values for imatinib ranged between 0.10 and 0.56 mM in the imatinib-sensitive cell lines LAMA84, K562, EM3 and BV173 (Table 1) . For 17-AAG, the IC 50 values were about 3-10-fold higher and varied between 1.08 and 2.07 mM (Table 1) . Combination treatment with simultaneous application of both compounds showed additive to slightly antagonistic effects, as indicated by CI values ranging between 1.04 and 1.47 at a 50% growth inhibition level (Table 1 ; Figure 1a , c, e and f). In primary CML cells (imatinibsensitive, blast crisis), growth inhibition of CFU-GM colonies in percent of untreated control was stronger after treatment with different concentrations of the combination of both drugs than after monotherapy resulting in additive (Figure 2a ) or synergistic effects of the combination treatment above affected fractions 40.4 and 40.5, respectively (Figure 2b and c) .
In imatinib-resistant LAMA84-R and K562-R cells, the IC 50 values of imatinib were 3.16 and 22.63 mM, respectively, that is, about 10-and 40-fold higher than in the corresponding imatinib-sensitive cell lines (Table 1 ). Compared to their imatinib-sensitive counterparts sensitivity to 17-AAG monotherapy was reduced as well in these lines, as indicated by IC 50 values of 14.23 and 7.65 mM, respectively, that is, about sevenand five-fold (crossresistance) ( Table 1) . Combination treatment of LAMA84-R and K562-R cells increased sensitivity towards both drugs since combination IC 50 values were reduced by a factor of 3 in LAMA84-R and a factor of 5 in K562-R as compared to single-agent treatment doses ( Table 1 ). The synergistic activity of imatinib plus 17-AAG in both resistant lines was corroborated by analysis of the combination effect according to the median effect method of Chou and Talalay. CI values significantly lower than 1 in LAMA84-R (CI ¼ 0.7670.09 at the 50% inhibition level, CI ¼ 0.6170.06 at the 75% inhibition level) and K562-R (CI ¼ 0.3970.04 at the 50% inhibition level, CI ¼ 0.5570.07 at the 75% inhibition level) were observed, indicating clear synergism (Table 1 ; Figure 1b and d). In primary CML cells derived from three patients refractory or resistant to imatinib therapy (imatinib-resistant, blast crisis (two patients) and chronic phase (one patient)) no colony growth both in untreated and treated groups could be observed (2 Â 10 4 -4 Â 10 5 MNC/assay) (data not shown).
Analysis of the ABL kinase domain sequence
The K562-R line displayed an increased resistance towards imatinib as compared to the original resistant K562-R line described by Mahon et al 8 (IC 50 : 22.63 vs 2 mM). To elucidate whether this difference was caused by kinase domain mutations, the entire ABL kinase domain of imatinib-sensitive K562 andresistant K562-R cells was sequenced and compared to published sequences. 20 No mutations were found in an 856-bp fragment, containing the ABL kinase domain, in both lines, which is consistent with previous results. 8 In comparison with monotherapy the combination of both drugs showed higher activity with regard to induction of early apoptosis both in sensitive and resistant cells. In imatinib-resistant LAMA84-R cells, a substantial increase in the early apoptotic cell fraction to 30.4473.12% occurred 
Induction of apoptosis
BCR-ABL protein expression and phosphorylation
BCR-ABL protein levels were higher in imatinib-resistant LAMA84-R and K562-R cells than in their sensitive counterparts (Figure 4a ). 17-AAG for 48 h reduced BCR-ABL protein levels in both resistant cell lines at a concentration of 10 mM. This effect was more pronounced after coincubation with imatinib plus 17-AAG (4 plus 10 mM, respectively), resulting in distinct suppression of BCR-ABL protein (Figure 4c and e) . Surprisingly, in LAMA84-R but not in K562-R, imatinib monotherapy (4 mM) decreased BCR-ABL protein levels as well. This effect was accompanied by a reduction of the intracellular Hsp90 level in LAMA84-R. 17-AAG alone did not lower Hsp90 levels but increased expression of Hsp70. In the sensitive lines, LAMA84 and K562 comparable effects with regard to mono-and combination therapy (including Hsp90 decrease) were observed at lower drug concentrations; here Hsp90 decrease following imatinib monotherapy was discernible in both lines (Figure 4b and d). 
Synergism of imatinib and 17-AAG A Radujkovic et al
To elucidate whether an inhibition of PDGFR is involved 21, 22 in the decrease of Hsp90 and BCR-ABL following imatinib monotherapy, we treated all four cell lines (K562, K562-R, LAMA84, LAMA84-R) with SU5614, a specific inhibitor of the PDGF receptor kinase. 23 However, no decrease of Hsp90 protein levels was observed (immunoblots not shown).
CRKL is the main target of the BCR-ABL tyrosine kinase and connector to downstream effector molecules. Analysis of the CRKL phosphorylation state showed a decrease of hyperphoshorylated CRKL in the imatinib-sensitive LAMA84 and K562 cells when cells were exposed to the highest dose of imatinib as monotherapy, whereas exposure to a combination of imatinib and 17-AAG showed a clear shift of the ratio of hyperphosphorylated and hypophosphorylated CRKL protein levels towards the hypophosphorylated form in a concentrationdependent manner (Figure 4b and d) . In the imatinib-resistant LAMA84-R and K562-R cells, the appearance of a hypophosphorylated CRKL band was only noted upon exposure to a combination of imatinib and 17-AAG at high concentrations of both drugs (4 plus 10 mM, respectively) (Figure 4c and e) .
BCR-ABL mRNA expression and FISH analysis
On the transcriptional level BCR-ABL mRNA, determined by quantitative real-time PCR, was found to be increased about 100-fold in LAMA84-R and about five-fold in K562-R as compared to the imatinib-sensitive lines LAMA84 and K562, respectively. FISH analysis of metaphase spreads from LAMA84 and LAMA84-R cells revealed a near triploid karyotype with numerical and structural chromosome aberrations including four Philadelphia chromosomes. In addition, LAMA84-R showed an amplification of the BCR-ABL rearrangement; this sequence was inserted in a translocation chromosome t(4;5). In contrast, both K562 and K562-R cells showed a Philadelphia chromosome with an amplified BCR-ABL rearrangement segment and an additional amplification of BCR-ABL in a derivative chromosome der(18)t(18;1;7;9;22) in both lines. Po0.005; for concentrations see Table 1 ).
Inhibition of Pgp function
Synergism of imatinib and 17-AAG
A Radujkovic et al cells to imatinib therapy described in vitro and in vivo. 4, 26 In clinical studies investigating imatinib resistance, this mechanism has been reported in 13% of CML patients refractory or resistant to imatinib. 5 Elevated BCR-ABL protein levels are sufficient to cause resistance to BCR-ABL tyrosine kinase inhibition. 27 This observation is obviously not due to a prolonged lifespan of the protein itself but rather due to BCR-ABL gene overexpression, as it correlates with an increase in BCR-ABL mRNA. 8 BCR-ABL expression can be modulated by imatinib itself, as withdrawal of the tyrosine kinase inhibitor from culture can lower the level of BCR-ABL. 8, 26, 28 Furthermore, overexpression of Pgp has been described as a mechanism conferring imatinib-resistance. 8, 9, 13 We could confirm these findings for the imatinib-resistant cell lines LAMA84-R and K562-R, which, besides BCR-ABL overexpression, were found to have increased Pgp activity as compared to their sensitive counterparts.
Systematic evaluation of the mechanisms of resistance of CML cells to imatinib shows that conditions leading to inefficient inhibition of the BCR-ABL tyrosine kinase function represent a critical event in disease progression under continuous imatinib therapy. If, as shown, cells are resistant to imatinib due to an increased amount of BCR-ABL protein or due to increased Pgp activity, regularly achievable intracellular drug concentrations will no longer be sufficient to inhibit all BCR-ABL tyrosine kinase molecules effectively, that is, effective concentrations of imatinib will be higher than achievable. Other compounds capable of reducing BCR-ABL protein levels or inhibiting Pgp function should therefore support the effect of imatinib either by reduction of target molecules or increment of intracellular imatinib concentrations.
The benzoquinone ansamycins geldanamycin and 17-AAG have been shown to exert antitumor activity in numerous preclinical models by inducing the proteasome-mediated degradation of important signal-transducing proteins. 29, 30 The BCR-ABL protein is associated with a chaperoning Hsp90 complex which provides stability and functional activity. Geldanamycin and 17-AAG disrupt the association of the BCR-ABL protein to Hsp90 and favor alternative binding to Hsp70. 31 This results in degradation of BCR-ABL via the proteasome pathway and subsequent decrease of cellular BCR-ABL protein levels, induction of apoptosis and differentiation in CML cell lines. 32, 33 Activity of geldanamycin and 17-AAG used as single agents in imatinib-resistant CML cells, which were identified to carry a point mutation in the BCR-ABL gene has recently been shown. The observed effect was even stronger than in the corresponding wild-type sensitive cell line. 34 In our experiments, the imatinib-resistant lines LAMA84-R and K562-R showed crossresistance for imatinib and 17-AAG when used as monotherapy; combination of both drugs, however, resulted in synergistic effects and sensitivity of leukemic cells was significantly increased. In imatinib-sensitive cell lines, combination effects were at best additive or marginally antagonistic, whereas in primary CML cells additive and synergistic effects could be observed. Consistent with previous reports we could show that the activity of imatinib and 17-AAG or their combination is mediated by apoptosis. 32, 33 For singleagent treatment with 17-AAG, concentrations for induction of apoptosis in both imatinib-resistant lines used in our study were higher than those used by Nimmanapalli et al 33 in K562 R ( þ BCR-ABL). The concentrations used in our study correspond to the IC 50 values and reflect the pronounced resistance/ crossresistance to 17-AAG and imatinib.
The increased resistance to imatinib of the K562-R line used in the present study (IC 50 420 vs 2 mM in the original resistant line described by Mahon et al 8 ) is not due to mutations in the ABL kinase domain, as could be demonstrated by sequence On the protein level, single-agent treatment with 17-AAG led, as expected, to an increase of intracellular Hsp70 as an indicator for activation of the proteasome pathway and to consecutive degradation of BCR-ABL. Combination treatment, which revealed notedly decreased BCR-ABL protein levels and dephosphorylation of CRKL, was even more effective in this respect. In contrast to experiments of Gorre et al 34 where wild type and mutant BCR-ABL protein levels in BCR-ABL-transduced Ba/F3 cells fell gradually after 24 h of exposure to 0.5-1.0 mM 17-AAG alone, our sensitive LAMA84 and K562 cells required a concentration of 2 mM 17-AAG for significant decrease of BCR-ABL protein. Thus, in our experiments with non-transduced BCR-ABL-positive CML cells a higher dose was needed. Interestingly, imatinib monotherapy reduced BCR-ABL protein levels in the imatinib-sensitive LAMA84 and K562 (1 mM imatinib) and in imatinib-resistant LAMA84-R (4 mM imatinib) cells; concomitantly determined Hsp90 levels were slightly decreased at both concentrations of imatinib (compared to untreated control levels). Since in imatinib-resistant K562-R cells, no BCR-ABL-protein-decreasing effect of imatinib monotherapy (4 mM) was observed and in this case Hsp90 protein levels remained unchanged, one might hypothesize that Hsp90 decrease is involved in BCR-ABL protein degradation following imatinib monotherapy. Jerome et al 21 reported that the Hsp90 level is among other factors regulated via PDGF. Since imatinib is an inhibitor of the PDGF receptor, 22 an interaction via this mechanism appeared to be conceivable. This consideration/ hypothesis, however, is not supported, since treatment of all four cell lines with SU5614, a specific PDGFR inhibitor, 23 revealed no decrease of Hsp90 protein levels.
A recent report by Illmer et al 13 disclosed imatinib to be a substrate of Pgp and showed increased efflux of imatinib in Pgp- 
A Radujkovic et al overexpressing cells. LAMA84-R cells were reported to overexpress Pgp. 8 It was therefore tempting to investigate the effect of 17-AAG on Pgp function. As a result, we show here for the first time that 17-AAG functionally inhibits Pgp-mediated 123 Rh efflux in a dose-dependent manner in cells displaying Pgp activity; this effect was most pronounced in LAMA84-R cells. In K562-R cells, 123 Rh efflux was increased by a factor of about 2 as compared to the sensitive line. In K562-R cells, too, 17-AAG or CsA treatment increased intracellular 123 Rh concentrations demonstrating distinct inhibition of a lower, as compared to LAMA84-R cells, Pgp activity. These results encourage the conclusion that 17-AAG might be able to inhibit Pgp-mediated imatinib efflux, thus increasing intracellular imatinib levels and contributing to the sensitivity of CML cells to imatinib by this mechanism as well.
17-AAG is currently undergoing clinical evaluation. 35 C max at the highest dose level was 16.71 mM (Banerji et al, Proc Am Assoc Cancer Res 2002; 43: 272, abstract). The 17-AAG concentrations used in our in vitro studies are thus achievable in a clinical setting.
In the present study, we demonstrate that combination of imatinib and 17-AAG has a favorable effect on BCR-ABLoverexpressing and Pgp-(over)expressing CML cells. Both drugs act synergistically. These findings support the hope for therapeutical improvement in CML using these antitumor agents.
